Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$710,000Cash on Hand
1.7mo Cash Runway
Follow NCEL by emailGet an email when NCEL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about NCEL, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 9, 2026 ·
Financing Announced a priced private placement of 471,125 common shares at $3.29 per share, a 20% premium to the November 6, 2026 close, plus warrants for 353,344 shares at $3.75. Closing is expected on or about November 23, 2026. Proceeds fund NCEL-101 IND-enabling work and working capital. Form 6-K · SEC filing · Press release
Nov 9, 2026 ·
Financing NewcelX plans a private placement of 471,125 common shares at $3.29 per share plus common warrants for 353,344 shares at $3.75, expected to bring $1.55 million in gross proceeds and closing on or about November 23, 2026. Proceeds will fund NCEL-101 for type 1 diabetes, including the IND-enabling toxicology study. Form 6-K · SEC filing
Nov 4, 2026 ·
Deal Entered a binding term sheet to sell its worldwide Mazindol portfolio to REA Holdings for $500,000 upfront ($30,000 cash, the rest in shares for a 9.4% stake), plus up to $55 million in milestones and 2% to 8% royalties. Closing requires definitive documentation. Form 6-K · SEC filing · Press release
Aug 20, 2026 ·
Financing Registers for resale up to 694,268 common shares held by selling shareholders, consisting of 347,134 shares issued in a July 2026 private placement and 347,134 shares issuable on exercise of warrants from that placement. Form F-3 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
NCEL holds $710,000 in cash and short-term investments and burns about $1.3M/quarter from operations,
an estimated runway of 1.7 months at that rate (BioRadar estimate, not company guidance).
Share count 4,797,505 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full NCEL picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NCEL and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.